1. TE-8105 首次人體臨床試驗研究：“First-in-human study of a long-acting GLP-1 receptor agonist (TE-8105) in overweight or obese adults without Type 2 diabetes mellitus” J. Clin. Pharm. 2026, 66: e70224. (https://doi.org/10.1002/jcph.70224) (影響因子為 2.2，為臨床藥理學與藥物開發領域具領導地位的國際期刊)
2. 多臂鏈接體平台：“Bioinorganic site-specific conjugation of multi-arm linkers to create pharmaceuticals with targeting and effector functions”J. Chin. Chem. Soc. 2026, 05 May. (https://doi.org/10.1002/jccs.70204) (榮獲 JCCS 邀稿撰寫 Review article，影響因子約 1.5)
3. TE-8105 舌下劑型：“Optimized sublingual delivery of dual fatty acid-conjugated GLP-1 receptor agonist TE-8105 produces durable efficacy in diabetic mice” Int J Pharma. 2026, 694:126752. (https://doi.org/10.1016/j.ijpharm.2026.126752) (影響因子為 5.2，在藥學與藥理學領域 366 種期刊中，引用次數排名第 3)
4. TE-8105：“2FA-platform generates dual fatty acid-conjugated GLP‑1 receptor agonist TE-8105 with enhanced diabetes, obesity, and NASH efficacy compared to semaglutide” J. Med. Chem. 2025, 68, 6178-6192. (https://doi.org/10.1021/acs.jmedchem.4c02153) (影響因子為 6.8，在藥物化學領域 72 種期刊中排名第 3)